Chris Dall | News Reporter | CIDRAP NewsMay 15, 2020One of the studies is the first published randomized controlled trial on the drug for COVID-19.
Studies find further lack of COVID benefit from hydroxychloroquine
Published in COVID-19
More from COVID-19More posts in COVID-19 »
- Very few US adults getting new flu, COVID, RSV vaccines, even in nursing homes
- US respiratory virus activity remains low ahead of holiday season
- Antiviral COVID-19 drug molnupiravir tied to large drop in deaths in older patients
- Adults with migraines at higher risk of depression during pandemic, study shows